Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Corporate Presentation up

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Mar 16, 2022 12:17pm

68 Views

Post# 34518701

RE:RE:RE:New Corporate Presentation up

I'd say you're right.

SPCEO1 wrote: It seems like it refers to the 2nd footnote which says this is the currently available dose. But I am not 100% sure of that. Probably 95% sure but wonder if there are other theories out there.

SPCEO1 wrote: Anyone want to take a guess as to what the blue "2" means under the first patient at the 300mg level?

SPCEO1 wrote: https://www.theratech.com/static-files/ddb819a0-33ef-485d-aae8-d587b8cb36bf

I don't think it tells us anything we did not already know or presume but have only had time to glance at it.